Nuvation Bio Inc. — Q2 2022 Form 10-Q
Business context and reporting period. Clinical-stage oncology biopharmaceutical company; unaudited quarter and six months ended June 30, 2022. The company had no approved products and generated no revenue. Its clinical-stage candidate NUV-868 began a Phase 1 study in March 2022; research and development also included preclinical programs and its Drug-Drug Conjugate platform.
Financial results and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $28.9m | $14.0m | $49.7m | $29.9m |
| General and administrative expense | $8.9m | $6.4m | $16.4m | $11.0m |
| Total operating expenses | $37.9m | $20.4m | $66.1m | $40.9m |
| Net loss | $34.9m | $19.3m | $56.2m | $39.7m |
| Net loss per share | $0.16 | $0.09 | $0.26 | $0.21 |
| Cash used in operating activities | Not separately stated | Not separately stated | $51.8m | $31.6m |
Balance sheet and liquidity at June 30, 2022: Cash and cash equivalents were $102.3m and marketable securities were $601.5m, totaling $703.8m. Total assets were $719.7m; current liabilities were $21.3m and total liabilities were $26.7m. The filing reports no borrowings; liabilities included $4.7m of operating lease obligations and $1.6m of warrant liability. Accumulated deficit was $219.0m. The company stated that available cash, cash equivalents and marketable securities should fund commitments for at least 12 months after issuance of the statements. It expects continuing operating losses and negative operating cash flows.
Cash flow detail: Six-month investing activities provided $21.1m, reflecting proceeds from securities sales exceeding purchases; financing provided $0.7m, principally option exercises and ESPP proceeds. Cash and cash equivalents declined $30.1m to $102.3m. The filing reports no off-balance-sheet arrangements. Profit margins are not meaningful because the company had no revenue.
Material changes versus the prior comparable period
- Q2 operating expenses rose $17.4m year over year, led by a $14.9m increase in R&D. Management attributed the R&D increase mainly to third-party research and manufacturing costs and higher personnel-related costs.
- Six-month operating expenses rose $25.1m, and net loss increased $16.4m. R&D increased $19.7m and G&A increased $5.4m.
- Operating cash use increased $20.3m for the first half. The prior-year period included $624.8m of net merger proceeds, while 2022 financing proceeds were limited.
- Marketable securities had $7.0m of unrealized losses at June 30, 2022, primarily attributed to interest-rate changes. The six-month comprehensive loss was $61.9m, including $5.8m of other comprehensive loss.
- Warrant fair-value gains reduced reported losses by $3.1m in Q2 and $9.4m for the first half; these were non-cash gains.
Outlook, commentary, risks and unusual items
- Post-quarter development: On August 1, 2022, the company announced it would discontinue NUV-422 clinical development after a uveitis safety signal in its monotherapy Phase 1/2 study and an internal risk-benefit review that included FDA feedback. It planned a third-quarter restructuring, reducing the workforce by 30 employees, approximately 35%, to lower costs and align staffing with remaining needs.
- The filing stated that, since February 2022, the company had discontinued or deprioritized three of the five programs it was then pursuing, including NUV-422.
- Management expects substantial future R&D and operating expenses and may need additional funding to complete development programs. The 12-month liquidity estimate depends on assumptions that could change; additional financing could dilute shareholders or require concessions of rights.
- Key risks include clinical and regulatory uncertainty, candidate safety and efficacy, reliance on third-party CROs and manufacturers, competition, intellectual-property protection, and potential disruption from COVID-19. Management said COVID-19 had not materially affected operations to date, but future effects remained uncertain.
- The company reported no pending significant legal proceedings expected to materially affect its financial position. Disclosure controls and procedures were assessed as effective at June 30, 2022.
Important facts for investors to verify
- Whether NUV-868 and the remaining development programs advance on schedule, and how the NUV-422 discontinuation affects portfolio plans and spending.
- The timing, costs, and completion of the planned workforce reduction, including any restructuring charges not quantified in this filing.
- Cash burn, investment portfolio value and liquidity runway as clinical development plans and expenses change.
- The nature and magnitude of future clinical safety findings, regulatory feedback, and trial enrollment or supply-chain delays.
- Potential dilution from outstanding options and warrants; the filing reports 21.2m options outstanding and 5.8m warrants at June 30, 2022.